We are live on
!
Find out more
GRCE
Grace Therapeutics
GRCE
GRCE
4 hedge funds and large institutions have $10K invested in Grace Therapeutics in 2013 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
4
Holders Change
+4
Holders Change %
–
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
No buyers this quarter
Top Sellers
No sellers this quarter
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $4K | +$3.61K | +3 | New |
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | +$2.41K | +2 | New |
|
3
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $2K | +$2.41K | +2 | New |
|
|
U
4
UBS
Zurich,
Switzerland
| $1K | +$1.2K | +1 | New |
|
GRCE Hedge Fund Activity: Q2 2013 in Review
4 of the 3,065 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q2 2013, worth a combined $10K.
Buyers outnumbered sellers: 4 funds opened new GRCE positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
- 4 institutional investors held Grace Therapeutics (GRCE) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $10K of Grace Therapeutics stock for Q2 2013.
- 4 funds opened new Grace Therapeutics positions in Q2 2013 and 0 closed out, a net change of +4 holders.
Based on aggregated 13F filings for Q2 2013.